<DOC>
	<DOCNO>NCT02004327</DOCNO>
	<brief_summary>1 . Objective After single dose healthy adult capacity Group DW1029M evaluate pharmacokinetic characteristic . 2 . Indication Diabetic kidney disease 3 . Efficacy 1 . Primary - AUClast , AUCinf , AUClast/D , AUCinf/D - Cmax , Cmax/D 2 . Secondary - Tmax , t1/2 , CL/F , Vz/F 4 . Safety 1 . Adverse Event Monitoring 2 . V/S , EKG , Laboratory Test , P/E</brief_summary>
	<brief_title>The Phase I Clinical Study Evaluate Pharmacokinetics Dw1029M Healthy Male Volunteer</brief_title>
	<detailed_description>Healthy volunteer clinical trial target drug administration date ( 1d ) within 3 week ( -21d ~-1d ) interview , physical examination laboratory test , include screen perform . Through screen deems appropriate clinical trial intend final subject randomize three group order . The first phase one clinical trial subject perform one day ( -1 ) 18:00 Chonbuk National University Hospital , convene physical examination perform hwalryeong sign . One person dinner , except drinking water fast . One clinical trial ( first day ) 20:00 subject randomly assign group accord order test administer single oral medication . The subject clinical trial 240 mL water , medicine swallow whole , chew swallow drug . Blood accord schedule clinical trial , include vital sign physical examination perform . The subject fix schedule discharge morning second . Is least one week washout period . Since two group accord order group three creep dose , except one tile proceed . After period three clinical trial , three day period take drug clinical trial 3-5 day perform post-study visit .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>More 20 year age time screen less 55 year old healthy male ( 17.5 ~ 30.5 kg/m2 body mass index ( BMI ) weight 45 kg â˜ž body mass index ( BMI ) = weight ( kg ) / height ( ) 2 No congenital chronic disease , internal medicine examination result psychotic symptom finding Clinically significant blood , kidney , endocrine , respiratory , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological , allergic disease ( include drug allergy , , time administration seasonal allergic untreated asymptomatic except sex ) , medical history evidence Drugs may affect absorption state ( eg , gastrectomy ) Investigational drug within two month first dose participated clinical trial</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>